SA00200872B1 - تراكيب وطرق للعلاج المناعي المتخصص ب wti - Google Patents

تراكيب وطرق للعلاج المناعي المتخصص ب wti Download PDF

Info

Publication number
SA00200872B1
SA00200872B1 SA00200872A SA00200872A SA00200872B1 SA 00200872 B1 SA00200872 B1 SA 00200872B1 SA 00200872 A SA00200872 A SA 00200872A SA 00200872 A SA00200872 A SA 00200872A SA 00200872 B1 SA00200872 B1 SA 00200872B1
Authority
SA
Saudi Arabia
Prior art keywords
ser
prt
pro
ala
gly
Prior art date
Application number
SA00200872A
Other languages
Arabic (ar)
English (en)
Inventor
مارتن شيفر
الكساندر جايجر
Original Assignee
كوريكسا كوربوريشن
جايجر, اليكساندر
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/164,223 external-priority patent/US7063854B1/en
Application filed by كوريكسا كوربوريشن, جايجر, اليكساندر filed Critical كوريكسا كوربوريشن
Publication of SA00200872B1 publication Critical patent/SA00200872B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4242—Transcription factors, e.g. SOX or c-MYC
    • A61K40/4243—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SA00200872A 1998-09-30 2000-01-22 تراكيب وطرق للعلاج المناعي المتخصص ب wti SA00200872B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/164,223 US7063854B1 (en) 1998-09-30 1998-09-30 Composition and methods for WTI specific immunotherapy
US27648499A 1999-03-25 1999-03-25

Publications (1)

Publication Number Publication Date
SA00200872B1 true SA00200872B1 (ar) 2007-01-30

Family

ID=26860363

Family Applications (1)

Application Number Title Priority Date Filing Date
SA00200872A SA00200872B1 (ar) 1998-09-30 2000-01-22 تراكيب وطرق للعلاج المناعي المتخصص ب wti

Country Status (25)

Country Link
EP (1) EP1117687B1 (cg-RX-API-DMAC7.html)
JP (3) JP4243792B2 (cg-RX-API-DMAC7.html)
KR (1) KR100752065B1 (cg-RX-API-DMAC7.html)
CN (1) CN100486995C (cg-RX-API-DMAC7.html)
AR (1) AR021849A1 (cg-RX-API-DMAC7.html)
AT (1) ATE399179T1 (cg-RX-API-DMAC7.html)
AU (1) AU6407899A (cg-RX-API-DMAC7.html)
BR (1) BR9914116A (cg-RX-API-DMAC7.html)
CA (1) CA2349442C (cg-RX-API-DMAC7.html)
CZ (1) CZ20011144A3 (cg-RX-API-DMAC7.html)
DE (1) DE69938970D1 (cg-RX-API-DMAC7.html)
ES (1) ES2310052T3 (cg-RX-API-DMAC7.html)
HK (1) HK1039782B (cg-RX-API-DMAC7.html)
HU (1) HUP0103598A3 (cg-RX-API-DMAC7.html)
IL (2) IL142216A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA01003344A (cg-RX-API-DMAC7.html)
MY (1) MY139226A (cg-RX-API-DMAC7.html)
NO (1) NO325839B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ510600A (cg-RX-API-DMAC7.html)
PL (1) PL201881B1 (cg-RX-API-DMAC7.html)
RU (1) RU2237674C2 (cg-RX-API-DMAC7.html)
SA (1) SA00200872B1 (cg-RX-API-DMAC7.html)
TR (1) TR200101482T2 (cg-RX-API-DMAC7.html)
TW (1) TWI285648B (cg-RX-API-DMAC7.html)
WO (1) WO2000018795A2 (cg-RX-API-DMAC7.html)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6805861B2 (en) 1996-01-17 2004-10-19 Imperial College Innovations Limited Immunotherapy using cytotoxic T lymphocytes (CTL)
AU4932199A (en) 1998-07-31 2000-02-21 Haruo Sugiyama Cancer antigens based on tumor suppressor gene wt1 product
US7115272B1 (en) 1998-09-30 2006-10-03 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7063854B1 (en) 1998-09-30 2006-06-20 Corixa Corporation Composition and methods for WTI specific immunotherapy
US7901693B2 (en) 1998-09-30 2011-03-08 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7655249B2 (en) 1998-09-30 2010-02-02 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20030072767A1 (en) * 1998-09-30 2003-04-17 Alexander Gaiger Compositions and methods for WT1 specific immunotherapy
US7144581B2 (en) 2000-10-09 2006-12-05 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7329410B1 (en) 1998-09-30 2008-02-12 Corixa Corporation Compositions and method for WT1 specific immunotherapy
US20030235557A1 (en) * 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
GB9823897D0 (en) * 1998-11-02 1998-12-30 Imp College Innovations Ltd Immunotherapeutic methods and molecules
WO2001025273A2 (en) * 1999-10-04 2001-04-12 Corixa Corporation Compositions and methods for wt1 specific immunotherapy
NZ521430A (en) * 2000-02-22 2004-04-30 Corixa Corp Compositions comprising 1-4 antigenic peptide fragments of the Wilms' tumour gene product for treatment or prevention of malignant mesothelioma
JP4592641B2 (ja) * 2000-05-24 2010-12-01 治夫 杉山 Wt1関連疾患の検査方法
JP3846199B2 (ja) 2000-05-24 2006-11-15 治夫 杉山 Wt1関連疾患の検査方法
CN1281625C (zh) * 2001-03-22 2006-10-25 株式会社癌免疫研究所 经修饰的wt1肽
WO2003002142A1 (fr) * 2001-06-29 2003-01-09 Chugai Seiyaku Kabushiki Kaisha Vaccin anticarcinogene contenant un antigene tumoral base sur un produit de gene wt1 suppresseur de tumeur et des liposomes cationiques
US7553494B2 (en) 2001-08-24 2009-06-30 Corixa Corporation WT1 fusion proteins
EP1447092A4 (en) * 2001-09-28 2007-07-11 Haruo Sugiyama METHODS OF INDUCING ANTIGEN-SPECIFIC T CELLS
US8735357B2 (en) 2001-09-28 2014-05-27 International Institute Of Cancer Immunology, Inc. Method of inducing antigen-specific T cells
WO2003106682A1 (ja) * 2002-06-12 2003-12-24 中外製薬株式会社 Hla−a24拘束性癌抗原ペプチド
EP1550453B1 (en) * 2002-09-12 2015-05-27 International Institute of Cancer Immunology, Inc. Cancer antigen peptide preparation
ATE442378T1 (de) * 2002-09-20 2009-09-15 Int Inst Cancer Immunology Inc Substituierte wt1-peptide
EP2154145B1 (en) * 2003-01-15 2013-04-24 International Institute of Cancer Immunology, Inc. Dimerized peptide
ES2478446T3 (es) * 2003-06-27 2014-07-22 International Institute Of Cancer Immunology, Inc. Método de selección de pacientes candidatos para la vacuna contra WT1
WO2005045027A1 (ja) 2003-11-05 2005-05-19 International Institute Of Cancer Immunology, Inc. Wt1由来のhla−dr結合性抗原ペプチド
PT1731605E (pt) * 2004-03-31 2010-04-14 Int Inst Cancer Immunology Inc Péptidos antigénicos de cancro derivados de wt1
EP1657250A1 (en) * 2004-11-11 2006-05-17 Charité - Universitätsmedizin Berlin HLA-A *01-binding T-cell epitope of WT1
RU2286146C1 (ru) * 2005-04-12 2006-10-27 Ростовский научно-исследовательский онкологический институт МЗ РФ Способ лечения церебральных метастазов генерализованной меланомы кожи
RU2301061C2 (ru) * 2005-04-28 2007-06-20 Ростовский научно-исследовательский онкологический институт МЗ РФ Способ лечения генерализованной меланомы кожи
SI1961761T1 (sl) 2005-11-30 2010-12-31 Int Inst Cancer Immunology Inc Nove peptidne spojine iz Wilmsovega tumorja
RU2435782C2 (ru) * 2006-02-22 2011-12-10 Интернешнл Инститьют Оф Кэнсер Иммунолоджи, Инк. Hla-a*3303-рестриктированный пептид wt1 и содержащая его фармацевтическая композиция
CA2915560A1 (en) * 2006-10-17 2008-04-24 Tomoaki Fujioka Peptide vaccines for cancers expressing mphosph1 or depdc1 polypeptides
RU2481398C2 (ru) 2006-12-28 2013-05-10 Интернешнл Инститьют Оф Кэнсер Иммунолоджи, Инк. Hla-a*1101-ограниченный пептид wt1 и содержащая его фармацевтическая композиция
MX352947B (es) 2007-02-27 2017-12-14 Int Inst Cancer Immunology Inc Metodo para activacion de celula t auxiliar y composicion para usarse en el metodo.
CA2678404C (en) * 2007-02-28 2019-03-19 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Brachyury polypeptides and methods for use
KR101773690B1 (ko) 2007-03-05 2017-08-31 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 암 항원 특이적 t 세포의 수용체 유전자 및 그것에 따라 코드되는 펩티드 및 이들의 사용
US20100255020A1 (en) * 2007-11-20 2010-10-07 Nec Corporation Method for inducing cytotoxic t-cells, cytotoxic t-cell inducers, and pharmaceutical compositions and vaccines employing them
WO2009072610A1 (ja) * 2007-12-05 2009-06-11 International Institute Of Cancer Immunology, Inc. 癌ワクチン組成物
AR076349A1 (es) 2009-04-23 2011-06-01 Int Inst Cancer Immunology Inc Peptido auxiliar del antigeno del cancer
ES2731343T3 (es) * 2009-05-19 2019-11-15 Univ Miami Composiciones, kits y métodos para presentación de antígenos in vitro, evaluación de eficacia de vacunas y evaluación de la inmunotoxicidad de productos biológicos y fármacos
SG189287A1 (en) 2010-10-05 2013-05-31 Int Inst Cancer Immunology Inc Method for activating helper t cell
ES2785081T3 (es) 2011-04-01 2020-10-05 Memorial Sloan Kettering Cancer Center Anticuerpos biespecíficos similares a receptores de células T específicos para un péptido de WT1 presentado por HLA-A2
US9803246B2 (en) 2011-06-28 2017-10-31 International Institute Of Cancer Immunology, Inc. Receptor gene for peptide cancer antigen-specific T cell
EP2868325B1 (en) 2012-07-02 2017-11-01 Sumitomo Dainippon Pharma Co., Ltd. Transdermal cancer antigen peptide preparation
AR094026A1 (es) 2012-12-17 2015-07-08 Otsuka Pharma Co Ltd Metodo para activar la celula t helper
EP2974734B1 (en) 2013-03-12 2018-10-10 Sumitomo Dainippon Pharma Co., Ltd. Liquid aqueous composition
WO2014157692A1 (ja) 2013-03-29 2014-10-02 大日本住友製薬株式会社 Wt1抗原ペプチドコンジュゲートワクチン
JP6671956B2 (ja) 2013-03-29 2020-03-25 大日本住友製薬株式会社 Erap1によるトリミング機能をきっかけとしたコンジュゲートワクチン
WO2014185387A1 (ja) * 2013-05-13 2014-11-20 株式会社癌免疫研究所 免疫療法の臨床効果の予測法
CN106170297A (zh) * 2013-09-20 2016-11-30 纪念斯隆-凯特琳癌症中心 用于wt‑1‑阳性疾病的组合/辅助疗法
EP3112378B1 (en) 2014-02-26 2020-06-24 Tella, Inc. Wt1 antigenic polypeptide, and anti-tumor agent containing said polypeptide
KR20230141904A (ko) * 2014-12-11 2023-10-10 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 혈관 신생병의 면역 요법
RU2743381C2 (ru) * 2015-09-10 2021-02-17 Мемориал Слоан-Кеттеринг Кэнсер Сентер Способы лечения множественной миеломы и плазмоклеточного лейкоза посредством т-клеточной терапии
HUE059694T2 (hu) * 2015-11-20 2022-12-28 Memorial Sloan Kettering Cancer Center Készítmény rák kezelésére
CN105254760B (zh) * 2015-11-21 2018-08-17 福州迈新生物技术开发有限公司 一株分泌抗wt1蛋白的单克隆抗体及其应用
WO2018101309A1 (ja) 2016-11-30 2018-06-07 大日本住友製薬株式会社 Wt1ヘルパーペプチド及びこれと癌抗原ペプチドコンジュゲート体との組合せ
EP3604325A4 (en) 2017-03-30 2021-01-13 Sumitomo Dainippon Pharma Co., Ltd. WT1 CANCER ANTIGEN PEPTIDE AND PEPTIDE CONJUGATE BODY WITH IT
CR20210160A (es) * 2017-04-10 2021-04-26 Immatics Biotechnologies Gmbh Péptidos y combinaciones de los mismos para el uso en la inmunoterapia contra diversos tipos de cáncer (divisional de solicitud 2019-0508)
PE20201149A1 (es) 2017-12-21 2020-10-26 Hoffmann La Roche Anticuerpos de union a hla-a2/wt1
CN109758575B (zh) * 2018-02-14 2022-08-30 上海微球生物科技有限公司 充分多样的双亲性mhc ii结合多肽、免疫载体微球及其制备方法和应用
JP7162675B2 (ja) 2018-09-28 2022-10-28 住友ファーマ株式会社 注射用組成物
TWI875736B (zh) 2019-02-28 2025-03-11 日商住友製藥股份有限公司 選擇可期待用於治療或預防癌之醫藥組合物之效果之對象之方法
KR20230009426A (ko) 2020-05-12 2023-01-17 스미토모 파마 가부시키가이샤 암을 처치하기 위한 의약 조성물
IL296209A (en) * 2020-05-12 2022-11-01 Cue Biopharma Inc Multimeric t-cell modulatory polypeptides and methods of using them
CN111647066B (zh) * 2020-07-01 2020-12-18 维肽瀛(上海)生物技术有限公司 Wt1多肽肿瘤抑制剂
KR20220034563A (ko) * 2020-09-11 2022-03-18 한국생명공학연구원 신규 치주 질환 특이 항체 및 이의 용도
KR102476515B1 (ko) * 2020-09-11 2022-12-12 한국생명공학연구원 치주 질환 특이 항체 및 이의 용도
TW202315645A (zh) 2021-08-12 2023-04-16 日商癌免疫研究所股份有限公司 用以處置或預防癌症之醫藥組合物及方法
WO2023048530A1 (ko) * 2021-09-24 2023-03-30 주식회사 차백신연구소 종양 연관 항원으로부터 유래된 펩타이드 및 리포펩타이드와 면역활성물질로 구성되는 아쥬번트를 포함하는 항암 백신 조성물 및 이의 용도

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3393867B2 (ja) * 1989-11-13 2003-04-07 マサチユーセツツ・インステイテユート・オブ・テクノロジー ウィルムス腫瘍遺伝子の位置決定と特徴付け
RU2100369C1 (ru) * 1992-04-22 1997-12-27 Варнер-Ламберт Компани Производные пептида или их фармацевтически приемлемые соли
US5705159A (en) * 1993-08-31 1998-01-06 John Wayne Cancer Institute Immunoreactive peptide sequence from a 43 KD human cancer antigen
US5622835A (en) * 1994-04-28 1997-04-22 The Wistar Institute Of Anatomy & Biology WT1 monoclonal antibodies
WO1999058135A1 (en) * 1998-05-11 1999-11-18 The Salk Institute For Biological Studies Compositions for the treatment of tumors, and uses thereof
AU4932199A (en) * 1998-07-31 2000-02-21 Haruo Sugiyama Cancer antigens based on tumor suppressor gene wt1 product

Also Published As

Publication number Publication date
CZ20011144A3 (cs) 2002-06-12
CA2349442C (en) 2012-12-04
EP1117687A2 (en) 2001-07-25
BR9914116A (pt) 2002-01-15
DE69938970D1 (de) 2008-08-07
PL201881B1 (pl) 2009-05-29
IL142216A0 (en) 2002-03-10
KR100752065B1 (ko) 2007-08-28
TWI285648B (en) 2007-08-21
MY139226A (en) 2009-08-28
AU6407899A (en) 2000-04-17
RU2237674C2 (ru) 2004-10-10
IL142216A (en) 2009-06-15
CA2349442A1 (en) 2000-04-06
NO20011613D0 (no) 2001-03-29
EP1117687B1 (en) 2008-06-25
JP4235984B2 (ja) 2009-03-11
CN1336935A (zh) 2002-02-20
TW200606176A (en) 2006-02-16
TR200101482T2 (tr) 2002-01-21
NZ510600A (en) 2003-12-19
AR021849A1 (es) 2002-08-07
ES2310052T3 (es) 2008-12-16
HK1039782B (en) 2008-11-14
MXPA01003344A (es) 2004-04-21
JP4243792B2 (ja) 2009-03-25
NO20011613L (no) 2001-05-29
HUP0103598A2 (hu) 2002-01-28
JP2002525099A (ja) 2002-08-13
JP2008069172A (ja) 2008-03-27
WO2000018795A9 (en) 2000-08-31
WO2000018795A2 (en) 2000-04-06
PL348595A1 (en) 2002-06-03
ATE399179T1 (de) 2008-07-15
JP2007001984A (ja) 2007-01-11
KR20010085861A (ko) 2001-09-07
NO325839B1 (no) 2008-07-28
CN100486995C (zh) 2009-05-13
HK1039782A1 (en) 2002-05-10
HUP0103598A3 (en) 2005-11-28
WO2000018795A3 (en) 2000-10-26

Similar Documents

Publication Publication Date Title
JP7097943B2 (ja) 免疫原性wt-1ペプチドおよびその使用法
RU2237674C2 (ru) Композиции и способы wt1-специфичной иммунотерапии
JP6298101B2 (ja) ヘルパーt細胞の活性化方法
TWI517859B (zh) 癌抗原輔助肽
KR101525261B1 (ko) Hla-a*1101 구속성 wt1 펩티드 및 이를 포함하는 의약 조성물
US20030194739A1 (en) Method of diagnosing, monitoring, staging, imaging and treating prostate cancer
RU2435782C2 (ru) Hla-a*3303-рестриктированный пептид wt1 и содержащая его фармацевтическая композиция
CZ2003440A3 (cs) Kompozice a způsoby pro terapii a diagnózu rakoviny vaječníků
EP0804483B1 (en) Isolated peptides derived from mage tumor rejection antigen precursors which complex with hla-a2 molecules
US20040152144A1 (en) Novel method of diagnosing, monitoring, staging, imaging and treating breast cancer
JP2003520606A5 (cg-RX-API-DMAC7.html)
JP2010000083A (ja) 腫瘍抗原タンパク質及びその利用
US20120177669A1 (en) Phosphopeptides as melanoma vaccines
JP2003502273A (ja) 正常な前立腺、精巣、および子宮ならびに新生物性の前立腺、精巣、および子宮に発現されたx連鎖gage様遺伝子であるpage−4、ならびにその使用
US20050049185A1 (en) Gene encoding a multidrug-resistance human P-glycoprotein homologue on chromosome 7p15-2 and uses thereof
US20040259084A1 (en) Diagnostic and therapeutic methods based on the l1 adhesion molecule for ovarian and endometrial tumors
US20090104177A1 (en) Peptides for inhibiting the interaction of protein kinase a and protein kinase a anchor proteins
RU2307666C2 (ru) Полинуклеотид, модулирующий пролиферацию раковых клеток (варианты), полипептид, моноклональное антитело, вектор экспрессии, клетка-хозяин, лекарственное средство для лечения пролиферативного заболевания, фармацевтическая композиция, применение полипептида для получения лекарственного средства
WO2004013311A2 (en) Compositions and methods relating to ovarian specific genes and proteins
US20040071726A1 (en) Peptide epitopes recognized by antigen specific cd4lymphocytes
WO2004015390A2 (en) Lung cancer target proteins and use thereof
De Leo et al. Properties of a M r 110,000 Tumor Rejection Antigen of the Chemically Induced BALB/c Meth A Sarcoma
AU714884B2 (en) Tumor rejection antigens presented by hla-b44 molecules, and uses thereof
CA2394914A1 (en) A novel method of diagnosing, monitoring, staging, imaging and treating cancer
HK1165482A (en) In tumours differentially expressed gene products and use of the same